ArticleAmerican journal of translational research2021
Application of vincristine and cisplatin combined with intensity-modulated radiation therapy in the treatment of patients with advanced cervical cancer.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Ligand-Based Drug Design of Genipin Derivatives with Cytotoxic Activity against HeLa Cell Line: A Structural and Theoretical Study.Pharmaceuticals (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effect of vincristine and cisplatin combined with intensity-modulated radiation therapy (IMRT) on the treatment of patients with advanced cervical cancer and its influence on adverse reactions.
methodsIn this retrospective clinical trial, 90 patients with advanced cervical cancer admitted to our hospital from January 2019 to January 2020 were collected as research subjects and were divided into two groups according to different treatment methods. The control group received IMRT, and the experimental group was treated with a triple therapy of vincristine, cisplatin, and IMRT. The clinical efficacy, incidence of adverse reactions, immune function indexes, serum indexes, and 3-year survival were compared between the two groups. The Generic Quality of Life Inventory-74 (GQOLI-74) questionnaire was used to assess the quality of life, and the Karnofsky Performance Scale (KPS) was used to evaluate the health status.
resultsThe experimental group exhibited a significantly higher total clinical treatment efficacy in comparison with the control group (P<0.05). Patients in the experimental group experienced fewer adverse reactions and better immune indexes as compared to those in the control group (all P>0.05). The serum indexes of the experimental group were significantly lower than those of the control group (P<0.05). Significantly higher GQOLI-74 scores and KPS scores were obtained in the experimental group than the control group after treatment (all P<0.05). The 3-year overall survival rate of the experimental group was significantly higher than that of the control group (P<0.05).
conclusionVincristine and cisplatin combined with IMRT for patients with advanced cervical cancer can effectively optimize the clinical indicators of patients and improve their quality of life, with a high safety.
Indexed as
Identifiers
35035730PMC8748177W4206857621What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.